We have provided ten tech companies focused on technologies related to diagnostics or patient identification, such as Glyconics, Renalytix AI, and Veracyte. Our findings can also be found below.
- Glyconics is producing a hand-held device to provide advance notice of acute events related to COPD. The device is powered by infrared spectrometry and will be the first of its kind in the world. The company hopes to begin trials on the product in 2019.
- The development of Glyconics’s infrared spectrometer tool has been conducted in conjunction with infrared spectrometry company Spectrolytic.
2. Renalytix A
- Renalytix AI is developing an AI-driven diagnostic tool for kidney disease, which was recently granted breakthrough drug designation by the US FDA. The device is called KidneyIntelX. The company currently has an “exclusive license and collaboration agreement with the Icahn School of Medicine at Mount Sinai in New York, USA.”
3. Avisa Pharma
- Avisa Pharma is currently developing BreathTest, which “is a biomarker, quantitative, point-of-care test for rapidly detecting pulmonary infections due to certain virulent pathogens without the need to collect and culture sputum or other biological samples.” The device will be able to detect “a wide range of severe respiratory infections with a high degree of sensitivity.”
- Avisa has partnered with Santa Fe-based company Southwest Sciences to develop the device.
- Veracyte is developing Percepta, a genomic sequencing classifier (GSC) that identifies if lung nodules found via CT scans are cancerous, identifying lung cancer patients without the need for “costly, invasive and often unnecessary procedures or to delayed treatment.”
- Veracyte has partnered with Johnson & Johnson on the Percepta project.
- 4Dx is developing a technology called 4DxV, which is a “four-dimensional lung function imaging analysis that uniquely and non-invasively measures lung function in real-time within the breathing lungs.” This could “provide more precise regional data” from lungs that can allow diagnosis of lung disease prior to severe symptoms developing, unlike current technologies such as spirometry.
6. Akonni Biosystems
- Akonni is currently working toward commercializing their proprietary TruArray technology, which “utilizes three-dimensional (3D) gel drop microarrays to rapidly screen a sample for hundreds of disease markers at one time, all within a microarray grid the size of your fingernail.” The TruArray technology will be utilized to detect tuberculosis, in conjunction with the company’s “TruDx® 3000 sample-to-answer diagnostic platform.”
- Akonni has formed a commercialization partnership in China with Chinese company Righton.
7. Huawei Cloud
- Huawei Cloud, a subsidiary of Chinese company Huawei, is pioneering an AI-powered diagnostic tool for cervical cancer. The tool can identify the disease with a “true positive rate of over 99.9 percent, and a true negative rate of more than 99 percent, which is currently the highest level in the world.”
- Huawei Cloud has partnered with Kingmed Diagnostics to produce the new AI technology.
- Genalyte is pioneering a blood testing system that would allow blood samples to be tested in minutes. This would allow for patient identification and diagnosis across a range of conditions. The company has an ongoing partnership with Kohsla Ventures with regard to its diagnostic platform.
- Minomic is developing a “quick, non-invasive” diagnostic tool called MiCheck to identify and diagnose individuals with prostate cancer. The test “works by measuring several protein biomarkers including a proprietary marker owned by Minomic called Glypican -1.”
- Minomic has partnered with Cirrus DX, which is “a CLIA Certified ‘High Complexity‘ Laboratory.” This will allow some US clinicians to get early access to the company’s novel MiCheck technology.
10. One Biomed
- One Biomed “is developing a point-of-care diagnostic platform deploying two proprietary technologies: a chemistry-based nucleic acid extraction and a silicon biophotonics dual-ring sensor.”
- The company established a laboratory, along with the Agency for Science, Technology and Research, to research assays that will be utilized in conjunction with this platform. These assays will be used to diagnose a variety of infectious diseases in Asia.
11. Itamar Medical
- Itamar Medical “develops, manufactures and markets non-invasive diagnostic medical devices” for sleep-related breathing disorders. Recently, the company announced the launch of its newest generation of home sleep diagnostics technologies, which allows for diagnosis outside of a clinical setting.
- Itamar Medical has partnered with CardioVisual for an educational initiative regarding sleep testing. The company has also partnered with Airway Management regarding distribution of some of its technologies.
- SomaLogic is a diagnostic company that is developing a technology, called SOMAscan, that “examines 5,000 body proteins from a single sample to identify a person’s genetic predispositions for more than 50 diseases and medical conditions,” allowing for patient identification across a range of illnesses.
- SomaLogic currently has a custom microarray supply partnership with Agilent, as well as a collaboration with Leeds Centre for Personalised Medicine to deliver its SOMAscan to patients there.
- AllerGenis is developing a novel diagnostic assay test to identify individuals with a range of food allergies. The company’s new technology “more than triples diagnostic precision compared to current food allergy tests.”
- AllerGenis is currently collaborating with Luminex on the food allergy diagnostic tool, using the latter’s xMAP technology to enhance the diagnostic tool’s “power and scope.“
14. Sherlock Biosciences
- Sherlock Biosciences’s flagship product is a diagnostic tool called SHERLOCK, based on the gene editing software CRISPR. Samples can be placed on small strips of paper, allowing results to be seen easily with the naked eye. The tool can “indicate presence of pathogens, tumor DNA, or any genetic signature of interest,” opening up a wide array of patient identification possibilities.
- Sherlock has partnered with Harvard University to utilize technology from the University’s Wyss Institute.
- Cerora’s flagship technology is a portable headset device called Cerora Borealis that allows for point-of-care testing for brain conditions. The technology’s potential applications are varied, and it may be used to test for anything from “mild Traumatic Brain Injury, to development disorders such as Autism, to brain tumors, and neurodegenerative conditions such as Alzheimer’s disease,” all in a remote setting.
- Cerora has partnered with Lehigh University, working with student athletes there. It has also partnered financially with Ben Franklin TechVentures.
16. AEIOU Scientific
- AEIOU is currently developing a “non-invasive osteoporosis diagnostic device” in conjunction with Ohio University’s Innovation Center. The new tool, called Cortical Bone Mechanics Technology, “uses a vibrating ceramic probe placed against the forearm. The bone under the skin vibrates in response.”
- AEIOU has partnered with Ohio University’s Innovation Center to produce the new osteoporosis diagnostic tool.
- IDx has developed an AI-powered opthomology diagnostic device that leverages an AI algorithm to diagnose eye conditions without the help of a live physician. It is reportedly the “first device authorized to provide a screening decision without the need for a specialized doctor to interpret the image or results.”
- IDx has partnered with Topcon to sell the former’s AI-based diagnostic system with the latter’s “NW400 robotic fundus camera.”
- CliniThink has developed an AI-driven technology called CLiX Enrich that gives companies in the healthcare and pharmaceutical space “ability to extract value from unstructured data.” One major application of this technology is patient identification for clinical trials, allowing companies to identify individuals with a given indication that they are seeking to treat.
- Northwell Health has partnered with CliniThink to employ the latter’s CLiX technology in the former’s clinical trial patient selection process.
19. Brain Sentinel Diagnostic Services LLC
- Brain Sentinel’s flagship product is the SPEAC system, which is a seizure diagnostic tool. The technology is “FDA cleared, first-of-its-kind, monitoring system advancing surface electromyography (sEMG) as a biomarker for seizures with a positive motor component.”
- Vizient has provided Brain Sentinel with an “Innovative Technology contract,” allowing for further development of the latter’s SPEAC system.
20. Enterome Biosciences
- Enterome has developed a Crohn’s disease diagnostic tool that is less invasive than traditional methods. The company “identified bacteria that are always downregulated or upregulated when the disease is active, and developed a test that can replace colonoscopy.”
- Enterome partnered with Nestle Health Sciences to produce the new test.
- Fibronostics is developing “blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease” called LiverFASt. The technology is “non-invasive, simple, and less expensive than liver biopsy or liver imaging.”
- Fibronostics has a wide range of partners, including SPRIM, the American Liver Foundation, Pappas Health, HealthLine, World Hepatitis Alliance, Convenient Care Association, and the Fatty Liver Foundation (FLF), among others.
22. Saw DX
- Saw DX is developing a portable patient sample diagnostic platform that is “built on unique acoustic-flow technology developed at the University of Glasgow’s School of Engineering.”
- The device is simple and provides fast results: “samples of patients’ blood, swabs or urine are placed on a disposable chip. The interaction between the sound waves and the chip enables the release of DNA and its amplification, potentially enabling test results in as little as 15 minutes.” The platform could potentially be utilized for a range of conditions.
- Saw DX is now collaborating with the UK’s innovation agency Innovate UK, which has supplied the firm with a grant to continue developing its novel technology.
- DxTerity is pioneering a genomic monitoring technology in which patients collect samples themselves at their homes (DxCollect) and submits them to a physician (DxDirect), who can easily monitor the patient’s RNA and identify if the patient has new or worsening conditions.
- The company has partnered with Duke University to develop a “genetic test for radiation exposure.”
24. T2 Biosystems
- T2 Biosystems has pioneered several diagnostic and patient identification innovations, including a novel sepsis-causing bacteria identifier and a fungal pathogen identifier.
- All of its diagnostic and identification technology is powered by its novel T2MR technology, which “is a diagnostic detection method utilizing miniaturized magnetic resonance technology which measures how water molecules react in the presence of magnetic fields.”
- T2 Biosystems and Cidara reached an agreement in which the latter would utilize T2MR technology to help test “Cidara’s novel echinocandin antifungal CD101 and increase the number of hospitals that adopt T2 Biosystems’ products.”
25. Preora Healthcare
- Preora Healthcare is attempting to leverage its proprietary PWS Nanocytology to “develop low-cost screening tests that improve the early detection of cancer.” This test could be used to identify patients that would most benefit from more invasive and costly procedures.
- Preora Healthcare and Planet Innovation are collaborating “in the development and commercialization of Preora’s sample-preparation technologies, and its proprietary Partial Wave Spectroscopy (PWS) Nanocytology platform.”
26. Agendia Inc.
- Agendia has developed two diagnostic patient identification technologies called MammaPrint and BluePrint. These technologies employ “Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology” to perform oncology diagnostic testing.
- Agendia has collaborated with a number of partners regarding these technologies, including Bluebee, Institute Curie, and Genecast Biotechnology Co.
- NovellusDx is employing CRISPR technology to develop “a breakthrough CRISPR gene-editing tool to successfully engineer multiple edits simultaneously to fragments of DNA extracted from a human cell.”
- This technology can be used to quickly identify which cancer patients would most benefit from which treatments, as “DNA samples that have been edited to present the precise genetic make-up of a patient’s cancer tumor can be used to rapidly screen multiple cancer drugs.”
- This technology was produced in collaboration with The Gene Editing Institute, which licensed the CRISPR technology to Novellus for use in development.
28. Path AI
- PathAI is developing a “computer vision-based pathology detection service” that allows for diagnosis and patient identification via computer vision, a form of artificial intelligence. Physicians currently use the technology “to determine the presence or absence of bacterium, viruses, cancerous cells or other disease-causing agents,” but the company is developing a newer version for use in clinical trials performed by pharmaceutical companies.
- PathAI has partnered with Philips “to develop solutions that improve the precision and accuracy of routine diagnosis of cancer and other diseases.”
- Prognos is developing an AI-driven patient identification technology that uses AI to “turn the data the company collected as Medivo [its former name] into a predictive engine, which helps payers and pharma companies spot diseases early and engage with their members or recruit for clinical trials.”
- Prognos has partnered with Datavant, a company “that deidentifies and protects patient data for shared use in research and treatment,” with regard to this patient identification technology.
30. Leben Care Technologies
- Leben Care is developing “artificial-intelligence (AI) based diagnostic and screening solutions, primarily known for automated, fast and affordable retinal screening.”
- The company’s technology “enables automated analysis of retina image using AI algorithms that can be used by technicians, nurses, optometrists to conduct basic screening with minimal specialist intervention, delivering real-time reports.”
- Leben Care has partnered with COSMOTEC to bring the former’s products to the Japanese market.